Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
IPO Year: 2018
Exchange: NASDAQ
Website: twistbioscience.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | $60.00 | Outperform | Wolfe Research |
| 6/4/2024 | $53.00 | Buy | Guggenheim |
| 1/17/2024 | $25.00 → $45.00 | Neutral → Buy | Goldman |
| 9/27/2023 | $27.00 | Buy | Berenberg |
| 1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
| 1/3/2023 | $28.00 → $36.00 | In-line → Outperform | Evercore ISI |
| 3/2/2022 | Outperform | Cowen | |
| 2/7/2022 | $130.00 → $75.00 | Overweight | Barclays |
| 2/7/2022 | $110.00 → $70.00 | Market Perform | SVB Leerink |
| 10/15/2021 | Outperform | Cowen |
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: March 26, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On March 23, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience Corporation for their SARS-CoV-2 NGS Assay. The SARS-CoV-2 NGS Assay is a next-generation sequencing (NGS) based test for the identification of SARS-CoV-2 RNA from respirato
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
4 - Twist Bioscience Corp (0001581280) (Issuer)
SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SCHEDULE 13G/A - Twist Bioscience Corp (0001581280) (Subject)
8-K - Twist Bioscience Corp (0001581280) (Filer)
10-Q - Twist Bioscience Corp (0001581280) (Filer)
144 - Twist Bioscience Corp (0001581280) (Subject)
144 - Twist Bioscience Corp (0001581280) (Subject)
8-K - Twist Bioscience Corp (0001581280) (Filer)
144 - Twist Bioscience Corp (0001581280) (Subject)
10-Q - Twist Bioscience Corp (0001581280) (Filer)
8-K - Twist Bioscience Corp (0001581280) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wolfe Research initiated coverage of Twist Bioscience with a rating of Outperform and set a new price target of $60.00
Guggenheim initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $53.00
Goldman upgraded Twist Bioscience from Neutral to Buy and set a new price target of $45.00 from $25.00 previously
Berenberg initiated coverage of Twist Bioscience with a rating of Buy and set a new price target of $27.00
Scotiabank initiated coverage of Twist Bioscience with a rating of Sector Outperform and set a new price target of $33.00
Evercore ISI upgraded Twist Bioscience from In-line to Outperform and set a new price target of $36.00 from $28.00 previously
Cowen resumed coverage of Twist Bioscience with a rating of Outperform
Barclays reiterated coverage of Twist Bioscience with a rating of Overweight and set a new price target of $75.00 from $130.00 previously
SVB Leerink reiterated coverage of Twist Bioscience with a rating of Market Perform and set a new price target of $70.00 from $110.00 previously
Cowen resumed coverage of Twist Bioscience with a rating of Outperform
Fastest customizable press release news feed in the world
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research. "We designed this panel to break the status quo in genomic profiling by offering laboratories a powerful alternative to locked, one-size-fits-all solutions," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "With our customizable c
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. "Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bios
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter fiscal 2025 ended June 30, 2025. "A strong balance sheet and disciplined cost-management underpin our focused business execution," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal third quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call a
HuTg can be coupled with Twist hyperimmune DiversimAb mouse model and B cell screening methods Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced the launch of a humanized transgenic (HuTg) mouse model to expand and complement its offering of antibody discovery services and further streamline monoclonal antibody discovery. "The humanized transgenic mouse model complements our current in vivo antibody discovery platforms and can be paired with our DiversimAb mouse and B cell screening platforms, offering researchers multiple methods that can be used independently or together to
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 70,254 equity awards, consisting of 56,182 restricted stock units ("RSUs") and up to 14,072 performance stock units ("PSUs"), to 36 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan and related form of restricted stock unit award agreement in accor
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 third quarter ended June 30, 2025, before the opening of the market on August 4, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Invest
Twist Gene Fragments shipped starting at two business days regardless of length, volume, configuration or delivery format Gene Fragments pricing from seven cents per base regardless of configuration, no hidden fees Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today accelerated its Express turnaround time for all Twist Gene Fragments with a turnaround time starting at two business days for both adapters off and adaptors on configurations. "We continue to iterate our manufacturing processes, enhancing and expanding our products to meet our customers' needs," said Emily M. Leproust, Ph.D
Offer end-to-end workflow from library prep through sequencing Twist to be sole provider of new Trinity™ library prep and target enrichment kits for Element AVITI™ sequencer Joint commercial activities to expand customer access to new NGS tools Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced an expanded collaboration to enable Element's AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows. This press release features multi
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events. About Twist Bioscience Corporation At Twist Bios
As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ:TWST) ("Twist" or the "Company"), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 72,991 equity awards, consisting of 53,600 restricted stock units ("RSUs") and up to 19,379 performance stock units ("PSUs"), to 36 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan and related form of restricted stock unit award agreement in accor
This live feed shows all institutional transactions in real time.
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G - Twist Bioscience Corp (0001581280) (Subject)
SC 13G - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
SC 13G/A - Twist Bioscience Corp (0001581280) (Subject)
Live finance-specific insights
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter fiscal 2025 ended June 30, 2025. "A strong balance sheet and disciplined cost-management underpin our focused business execution," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal third quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call a
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 third quarter ended June 30, 2025, before the opening of the market on August 4, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Invest
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal second quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its f
Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital Partners, Earth Foundry, Rsquared VC, In-Q-Tel (IQT), and other undisclosed investors Varun Mehta, previously founder of Nimble Storage, to serve as CEO of Atlas Data Storage Twist remains focused on serving customers across the life sciences spectrum and expanding rev
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, before the opening of the market on May 5, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal first quarter 2025 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss it
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, before the opening of the market on February 3, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024. Visit the Events and Presentations page of the Investor Relations section under the "Company" tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2024 earnings report and the investor presentation, or click https://investors.twistbioscience.com/events-and-presentations. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. E
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, before the opening of the market on November 18, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to
– Record revenue of $81.5M in 3QFY24, an increase of 28% over $63.7M in 3QFY23 – – Gross margin improved to 43.3% in 3QFY24, increasing approximately 900 basis points over 34.4% in 3QFY23 – — Increased FY 2024 revenue guidance to approximately $310M to $311M; FY 2024 gross margin guidance at high end of the range at approximately 42.0% — — Company to host conference call today at 8:00 a.m. Eastern Time — Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2024 ended June 30, 2024. "We
Live Leadership Updates
Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of directors. She will also serve as a member of the audit committee. Ms. Shineman Blake most recently served as chief executive officer of Vistaprint, a Cimpress company, and brings nearly three decades of experience across multiple strategic areas including corporate governance, customer experience, digital transformation and global marketing. "Trynka is an accomplished global leader with a proven track record of driving profitable growth and innovation of custom products at scale," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bios
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241008118663/en/Mike Fero, Ph.D., CIO of Twist Bioscience (Photo: Business Wire) "Mike's extensive background in building and configuring scalable enterprise softwar
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings experience across small cap and Fortune 50 companies along with a track record of collaborating across teams to drive profitable growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240105333128/en/Adam Laponis, chief financial officer of Twist Bioscience (Photo: Business Wire) "Adam's deep financial acumen and strategic planning expertise across diverse businesses make him
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mark Buck as senior vice president, operations. Mr. Buck brings experience improving manufacturing efficiency and driving revenue and margin through managing supply chain and operations, including planning, quality, procurement and logistics. "Building on the foundation of his time serving in the United State Marine Corps and drawing from military efficiency, Mark has established a career in industry developing and optimizing operational processes and requirements that enable scale for multiple
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Chet Gandhi as chief information officer. Mr. Gandhi brings a wealth of experience in leading and executing software and information technology strategies to enable the growth of global public and private companies. "With a strong track record of success, Chet's expertise will play a crucial role in driving automation and supporting Twist's expansion efforts as we strive to grow our customer base from over three thousand to over one hundred thousand," said Emily M. Leproust, Ph.D., CEO and co-f
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer. "Rob has a proven track record of leading corporate and technical accounting, including for global companies as they grow in revenue," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "He will be an invaluable addition as Twist continues to gain market share and execute against our plan to achieve adjusted EBITDA breakeven for the core and biopharma businesses at the close of the fiscal fourth quarter of 2024." "I have spent the
BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Steffen Hellmold to the newly created position of senior vice president, business development, data storage. "We have made significant technological advances in our DNA data storage division and are now focused on laying the foundation for commercialization of this disruptive and important storage solution. The addition of Steffen to the team will help to define our commercialization strategy and build important relationships as we move towards more accessible DNA data storage solutions," commen
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Dennis Cho as senior vice president, general counsel and chief ethics and compliance officer. Mr. Cho brings more than 25 years of corporate legal experience, most of which has been in the biotech industry. "Dennis is a giant of biopharma deals with a proven track record in, and commitment to, the biotech industry. He has provided counsel on all types of transactions and collaborations, which makes him ideal for the role at Twist," commented Emily M. Leproust, Ph.D., CEO and co-founder of Twist
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it appointed Melissa Starovasnik, Ph.D. to its board of directors. Dr. Starovasnik most recently served as Senior Scientific Advisor, Research at Genentech, Inc. and brings nearly three decades of experience in protein and antibody drug discovery and development. "Melissa's extensive leadership and scientific experience will be valuable to Twist as we leverage our DNA platform to support our broad base of customers across the synthetic biology and biopharmaceutical industries," said Emily M. Leproust, Ph.D., CEO a